June 30, 2020 / 11:16 AM / 7 days ago

BRIEF-Can-Fite Announces Final Data Analysis From Phase Ii Nash Study Highly Significant

June 30 (Reuters) - Can Fite Biopharma Ltd:

* CAN-FITE ANNOUNCES FINAL DATA ANALYSIS FROM PHASE II NASH STUDY: HIGHLY SIGNIFICANT AND SUSTAINED REDUCTION IN LIVER FAT VOLUME THROUGHOUT STUDY PERIOD

* CAN FITE BIOPHARMA LTD - HIGHLY SIGNIFICANT AND SUSTAINED REDUCTION IN LIVER FAT VOLUME THROUGHOUT STUDY PERIOD

* CAN FITE BIOPHARMA LTD - NAMODENOSON CONTINUES TO DEMONSTRATE A VERY GOOD SAFETY PROFILE AFTER DRUG TREATMENT

* CAN FITE BIOPHARMA LTD - RESULTS CONFIRM 25 MG NAMODENOSON AS OPTIMAL DOSE BASED ON MRI-PDFF ANALYSIS AND LIVER ENZYMES

* CAN FITE BIOPHARMA LTD - DATA SHOW THAT NAMODENOSON AT 25 MG DOSE PRODUCED STATISTICALLY SIGNIFICANT RESULTS IN ALL MEASURES OF EFFICACY

* CAN FITE BIOPHARMA LTD - NAMODENOSON CONTINUED TO BE SAFE AND VERY WELL TOLERATED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below